Treatment GuideJust DiagnosedSex & DatingAfrican AmericanStigmaAsk the HIV DocPrEP En EspañolNewsVoicesPrint IssueVideoOut 100
CONTACTCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2023 Pride Publishing Inc.
All Rights reserved
All Rights reserved
By continuing to use our site, you agree to our Private Policy and Terms of Use.
In a Phase II clinical trial, Merck experimental integrase inhibitor raltegravir (Isentress) demonstrated positive results for both treatment-experienced and treatment-naive patients, according to researchers. In the study of patients with resistance to protease inhibitors, nucleoside reverse transcriptase inhibitors, or nonnukes, at week 24 of receiving raltegravir 71% achieved viral loads below 400, compared to 16% receiving a placebo. ----- ----- ----- In another Phase II trial, reported in July at the International AIDS Society conference, patients achieved undetectable viral loads (less than 50) with all four doses of raltegravir studied (100, 200, 400, or 600 milligrams twice daily) in treatment-naive patients infected with HIV. In addition, raltegravir showed minimal impact on total and LDL ('bad') serum cholesterol, serum triglycerides, and the ratio of total cholesterol to HDL cholesterol. ----- ----- ----- In a Phase III study comparing a once-daily treatment regimen of Truvada and Sustiva to a twice-daily regimen of Combivir with once-daily Sustiva, reported by Gilead Sciences, after 144 weeks of treatment the Truvada-Sustiva regimen was associated with significantly greater virologic suppression compared to the Combivir-based regimen and also caused greater increases in CD4 cell counts and fewer side effects. ----- ----- ----- Testosterone MD-Lotion effectively and safely restored testosterone levels into the normal range with no adverse side effects, according to results of an eight-month Phase II trial reported by Australian biotech company Acrus. The lotion is dosed via a roll-on applicator to the armpits of men with low testosterone levels. ----- ----- ----- Tibotec Pharmaceuticals filed in late July with the Food and Drug Administration an application for approval to sell etravirine (also known as TMC-125), a new candidate in the nonnuke class of antiretrovirals. ----- ----- ----- Boehringer Ingelheim has started enrolling patients for a Phase IIIb trial of protease inhibitor Aptivus, which will look at the efficacy of the drug across a range of race and gender. The project will examine safety, efficacy, and pharmacokinetics in a racially diverse group of 200 female and 200 male treatment-experienced patients across eight countries at 72 sites on three continents.
Want more breaking equality news & trending entertainment stories?
Check out our NEW 24/7 streaming service: the Advocate Channel!
Download the Advocate Channel App for your mobile phone and your favorite streaming device!
From our Sponsors
Most Popular
Plus: Featured Video
Latest Stories
The Pride Store: Discover More LGBTQ+ & Ally Brands Tailor Made for Celebrating Your Identity
November 30 2023 3:04 PM
Shop Your Pride: Dive into LGBTQ+ & Ally Brands with The Grand Opening of The Pride Store
November 28 2023 5:32 PM
These Black Queer Podcasts (Featuring Literally Zero Cis White Gay Men) Deserve Your Ears
November 28 2023 11:55 AM
7 Uplifting Films To Celebrate Trans Awareness Week & Where To Stream Them
November 17 2023 10:25 AM
Out's Deal Guide: Grab Your 50% Off Amazon Fire Tablets & More Recommended Deals on Amazon Today!
November 03 2023 3:44 PM
Unlock Massive Savings at 'The Holiday Shop': Amazon's Hottest Deals of the Season Await!
November 02 2023 2:17 PM
Dianne Feinstein’s Commitment to People Living With HIV Won’t Be Forgotten
November 02 2023 1:27 PM
Trending stories
Most Recent
Recommended Stories for You
Plus Editors
Editor
Ryan is the Digital Director of The Advocate Channel, and a graduate of NYU Tisch's Department of Dramatic Writing. She is also a member of GALECA, the LGBTQ+ society of entertainment critics. While her specialties are television writing and comedy, Ryan is a young member of the LGBTQ+ community passionate about politics and advocating for all.
Ryan is the Digital Director of The Advocate Channel, and a graduate of NYU Tisch's Department of Dramatic Writing. She is also a member of GALECA, the LGBTQ+ society of entertainment critics. While her specialties are television writing and comedy, Ryan is a young member of the LGBTQ+ community passionate about politics and advocating for all.